{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:46:52Z","timestamp":1790740012789,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bmc.2021.116208","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T18:58:08Z","timestamp":1620586688000},"page":"116208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives"],"prefix":"10.1016","volume":"41","author":[{"given":"Osamu","family":"Kubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kamaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Tsujihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Odani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kitazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116208_b0005","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bmc.2021.116208_b0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2009.06.002","article-title":"Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors","volume":"124","author":"Verspohl","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2021.116208_b0015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/13543784.17.6.845","article-title":"Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes","volume":"17","author":"Mikhail","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmc.2021.116208_b0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.bmc.2021.116208_b0025","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/en.2006-1608","article-title":"A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release","volume":"148","author":"Chu","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bmc.2021.116208_b0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/B978-0-12-381517-0.00016-3","article-title":"GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders","volume":"84","author":"Shah","year":"2010","journal-title":"Vitam Horm"},{"key":"10.1016\/j.bmc.2021.116208_b0035","first-page":"519","article-title":"GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders","volume":"12","author":"Shah","year":"2009","journal-title":"Curr Opin Drug Discov Dev"},{"key":"10.1016\/j.bmc.2021.116208_b0040","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/13543770903153878","article-title":"GPR119 agonists for the treatment of type 2 diabetes","volume":"19","author":"Jones","year":"2009","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmc.2021.116208_b0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17460441.3.4.403","article-title":"GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity","volume":"3","author":"Fyfe","year":"2008","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmc.2021.116208_b0050","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1038\/sj.bjp.0707529","article-title":"GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity","volume":"153","author":"Overton","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2021.116208_b0055","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.bmc.2014.01.028","article-title":"Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists","volume":"22","author":"Sato","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116208_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116034","article-title":"Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach","volume":"34","author":"Kamaura","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2021.116208_b0065","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1016\/S0040-4039(00)74682-X","article-title":"A facile synthesis of trifluoromethylamines by oxidative desulfurization-fluorination of dithiocarbamates","volume":"33","author":"Kuroboshi","year":"1992","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmc.2021.116208_b0070","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1246\/bcsj.71.1973","article-title":"A Facile Synthesis of Trifluoromethylamines by oxidative desulfurization\u2013fluorination of dithiocarbamates","volume":"71","author":"Kiyoshi","year":"1998","journal-title":"Bull Chem Soc Jpn"},{"key":"10.1016\/j.bmc.2021.116208_b0075","unstructured":"MOE. (Molecular Operating Environment) Software. Version: MOE; vol 2012.10. QC, Canada: Chemical Computing Group, M. MOE (Molecular Operating Environment) software. Version: MOE. Montreal, QC, Canada: Chemical Computing Group; 2012.10."},{"key":"10.1016\/j.bmc.2021.116208_b0080","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2021.116208_b0085","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1021\/jm060379l","article-title":"Medicinal chemistry of hERG optimizations: highlights and hang-ups","volume":"49","author":"Jamieson","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2021.116208_b0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"B\u00f6hm","year":"2004","journal-title":"ChemBioChem"},{"key":"10.1016\/j.bmc.2021.116208_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/ci7002494","article-title":"Small molecule conformational preferences derived from crystal structure data. A medicinal chemistry focused analysis","volume":"48","author":"Brameld","year":"2008","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2021.116208_b0100","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1126\/science.1131943","article-title":"Fluorine in pharmaceuticals: looking beyond intuition","volume":"317","author":"M\u00fcller","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bmc.2021.116208_b0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/cmdc.200800321","article-title":"Assessing the bioisosterism of the trifluoromethyl group with a protease probe","volume":"4","author":"Jagodzinska","year":"2009","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.bmc.2021.116208_b0110","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1248\/cpb.c13-00436","article-title":"Impact of physicochemical profiling for rational approach on drug discovery","volume":"61","author":"Nakashima","year":"2013","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"3","key":"10.1016\/j.bmc.2021.116208_b0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1248\/yakushi1947.115.3_213","article-title":"Studies of novel 1,4-dihydropyridine Ca antagonist CS\u2212905. I. Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC)","volume":"115","author":"Masumoto","year":"1995","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.bmc.2021.116208_b0120","doi-asserted-by":"crossref","first-page":"C1437","DOI":"10.1107\/S2053273314085623","volume":"70","author":"Sheldrick","year":"2014","journal-title":"Acta Cryst A"},{"key":"10.1016\/j.bmc.2021.116208_b0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1107\/S0108767307043930","volume":"64","author":"Sheldrick","year":"2008","journal-title":"Acta Cryst A"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621002169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621002169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:13:17Z","timestamp":1760836397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621002169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":25,"alternative-id":["S0968089621002169"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116208","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116208"}}